{"id":52350,"date":"2026-03-31T10:30:10","date_gmt":"2026-03-31T10:30:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/52350\/"},"modified":"2026-03-31T10:30:10","modified_gmt":"2026-03-31T10:30:10","slug":"novo-nordisk-cuts-ozempic-and-wegovy-prices-by-up-to-48-as-glp-1-competition-intensifies-in-india","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/52350\/","title":{"rendered":"Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India"},"content":{"rendered":"<p>As the pricing war in India\u2019s GLP-1 therapy market intensifies, Danish drugmaker <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/novo-nordisk\" target=\"_blank\" rel=\"nofollow noopener\">Novo Nordisk<\/a> has sharply reduced prices of its blockbuster semaglutide brands <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/ozempic\" target=\"_blank\" rel=\"nofollow noopener\">Ozempic<\/a> and <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/wegovy\" target=\"_blank\" rel=\"nofollow noopener\">Wegovy<\/a> to expand patient access.<\/p>\n<p>The starting price of Ozempic has been cut by 36%, while Wegovy has seen a steeper 48% reduction.<br \/>This brings the base price of both brands at par at Rs 5,660 per month for treatment.<\/p>\n<p>The new prices in India will be effective from April 1.<\/p>\n<p>ET was the first to report that Novo Nordisk was planning a price cut, targeting a monthly range of Rs 5,000\u20136,000.<\/p>\n<p><img decoding=\"async\" alt=\"ET logo\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/118783427.cms.png\" width=\"90%\"\/>Live Events<br \/>\u201cThe latest price cuts are aimed at making the therapies more accessible to a larger section of people living with diabetes and obesity in India,\u201d Novo Nordisk India head Vikrant Shrotriya told ET.<br \/>Ozempic, indicated for type 2 diabetes management, will be available in price range of Rs 5,660 to Rs 8,100 for its three dosages (0.25 mg, 0.5 mg and 1 mg). Wegovy, indicated for chronic weight management, will be priced in the range of Rs 5,660-Rs 16,400 across five available dosages (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg) Compared to this, Eli Lilly\u2019s <a ref=\"dofollow\" data-ga-onclick=\"Inarticle articleshow link click#Industry#href\" href=\"https:\/\/m.economictimes.com\/topic\/mounjaro\" target=\"_blank\" rel=\"nofollow noopener\">Mounjaro<\/a> (tirzepatide) costs between Rs 13,000 and Rs 26,000 per Kwikpen, depending on the dosage. Each pen contains four weekly doses.<\/p>\n<p>Sun Pharmaceuticals, Dr Reddy\u2019s Laboratories and Zydus Lifesciences are among large Indian companies that rolled out generic semaglutide on the first day of patent expiry on March 21.<\/p>\n<p>Dr Reddy\u2019s has priced its GLP1 injection Obeda at Rs 4,200 per month, while Sun\u2019s prices for weekly therapy are Rs 900-2,000 for Noveltreat (indicated for chronic weight management) and Rs 750-1,300 for Sematrinity (indicated for treatment of type-2 diabetes). Zydus\u2019 semaglutide injection on average costs Rs 2,200 for a month.<\/p>\n<p>Companies like Natco and Eris have introduced more affordable vial options, priced as low as Rs 1,290 for a month\u2019s supply.<\/p>\n","protected":false},"excerpt":{"rendered":"As the pricing war in India\u2019s GLP-1 therapy market intensifies, Danish drugmaker Novo Nordisk has sharply reduced prices&hellip;\n","protected":false},"author":2,"featured_media":52351,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[28977,28976,6304,272,3102,1910],"class_list":{"0":"post-52350","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-drug-pricing-war-india","9":"tag-glp-1-therapy-india","10":"tag-mounjaro","11":"tag-novo-nordisk","12":"tag-ozempic","13":"tag-wegovy"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116323328116772763","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/52350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=52350"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/52350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/52351"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=52350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=52350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=52350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}